Duorui Pharmaceutical released its 2026 half-year report, with net profit attributable to the parent company of 11.53 million yuan for the first half, turning from a loss of 42.5 million yuan in the same period last year. Operating revenue was 95.66 million yuan, down 10.2 percent year on year. Net profit attributable to the parent company excluding non-recurring items was a loss of 33.44 million yuan, narrower than the loss of 45.52 million yuan a year earlier. Net operating cash flow was negative 44.43 million yuan, down 66.8 percent year on year. In the second quarter, operating revenue was 63.22 million yuan, up 10.7 percent year on year, and net profit attributable to the parent company was 25.5 million yuan, compared with a loss of 26.91 million yuan a year earlier. The company said that because its core product, Sodium Acetate Ringer's Injection, won centralized procurement bids and due to business adjustments, its formulation and distribution business shrank sharply year on year, but the scale and share of its chemical intermediates and peptide active pharmaceutical ingredients business rose significantly, further diversifying its business layout.
Tibet Duo Rui Pharmaceutical Co.Ltd.Swings to net profit of 11.53 million yuan from a loss, though revenue fell and ex-items loss narrowed.
